お知らせ • Mar 14
HanulBnC CO.,LTD, Annual General Meeting, Mar 28, 2025 HanulBnC CO.,LTD, Annual General Meeting, Mar 28, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 289, jangmal-ro, gyeonggi-do, bucheon South Korea お知らせ • Mar 05
NewGLAB Pharma CO.,LTD announced that it has received KRW 6.835 billion in funding from Namhwa Corporation, SLP Co. Ltd. and other investors On March 4, 2024, NewGLAB Pharma CO.,LTD closed the transaction. お知らせ • Feb 23
NewGLAB Pharma CO.,LTD announced that it expects to receive KRW 6.835 billion in funding from Namhwa Corporation, SLP Co. Ltd. and other investors NewGLAB Pharma CO.,LTD announced a private placement to issue 13,670,000 common shares at an issue price of KRW 500 per share for the gross proceeds of KRW 6,835,000,000 on February 22, 2024. The transaction included participation from new investors H&Y Holdings Co., Ltd. 5,600,000 shares, APIC Co., Ltd. 2,000,000 shares, Namu Invest Co., Ltd. 800,000 shares, Namhwa Corporation 400,000 shares and SLP Co. Ltd. 400,000 shares and individual investors OO Kim for 1,120,000 shares, OO Yoon 2,000,000 shares, OO 400,000 shares, LeeOO 400,000 shares and Seo OO 150,000 shares. The transaction has been approved by the shareholders of the company and is expected to closed on March 4, 2024. The securities are restricted to a hold period. Reported Earnings • Mar 18
Full year 2022 earnings released: ₩2,201 loss per share (vs ₩1,662 loss in FY 2021) Full year 2022 results: ₩2,201 loss per share (further deteriorated from ₩1,662 loss in FY 2021). Revenue: ₩21.7b (down 26% from FY 2021). Net loss: ₩69.6b (loss widened 38% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 49% per year, which means it has not declined as severely as earnings. Buying Opportunity • Aug 24
Now 25% undervalued Over the last 90 days, the stock is up 38%. The fair value is estimated to be ₩17,476, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 24% over the last 3 years. Earnings per share has declined by 56%. お知らせ • Apr 07
NewGLAB Pharma CO.,LTD announced that it has received KRW 25 billion in funding from DB Financial Investment Co.,Ltd., Investment Arm On April 5, 2022, NewGLAB Pharma CO.,LTD closed the transaction. お知らせ • Mar 23
NewGLAB CO.,LTD announced that it has received KRW 9.23 billion in funding On March 22, 2021, NewGLAB CO.,LTD (KOSDAQ:A214870) closed the transaction. Reported Earnings • Mar 17
Full year 2020 earnings released: ₩834 loss per share (vs ₩190 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: ₩54.4b (down 43% from FY 2019). Net loss: ₩22.6b (loss widened 464% from FY 2019). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth. お知らせ • Mar 14
NewGLAB CO.,LTD announced that it expects to receive KRW 9.23 billion in funding NewGLAB CO.,LTD (KOSDAQ:A214870) announced a private placement of series 7 non-guaranteed private convertible bonds with bearer interest with for gross proceeds of KRW 9,230,000,000 on March 12, 2021. The transaction will include participation from Hyun-cheol Noh for KRW 3,230,000,000 and Seong-su Cho for KRW 6,000,000,000. The bonds are zero coupon bonds and bears fixed interest rate to maturity of 2%. The bonds will mature on March 22, 2024. The bonds are 100% convertible into 699,242 shares, representing 2.28%, at a fixed conversion price of KRW 13,200 per share. The conversion period starts from March 22, 2022 and ends on February 22, 2024. The subscription date is March 12, 2021 and the transaction is expected to close on March 22, 2021. The transaction has been approved by the company's board of directors. The bonds carry a hold period of one year. Is New 90 Day High Low • Feb 18
New 90-day low: ₩10,900 The company is down 15% from its price of ₩12,850 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 41% over the same period. Is New 90 Day High Low • Jan 27
New 90-day low: ₩11,850 The company is down 12% from its price of ₩13,500 on 29 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 57% over the same period. Is New 90 Day High Low • Nov 11
New 90-day low: ₩12,750 The company is down 4.0% from its price of ₩13,300 on 13 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 3.0% over the same period. お知らせ • Sep 29
NewGLAB CO.,LTD announced that it expects to receive KRW 35 billion in funding from DB Financial Investment Co.,Ltd., Investment Arm NewGLAB CO.,LTD (KOSDAQ:A214870) announced a private placement of series 6 non-guaranteed private convertible bonds with bearer interest for gross proceeds of KRW 35,000,000,000 on September 28, 2020. The transaction will include participation from returning investor DB Financial Investment Co.,Ltd., Investment Arm. The bonds are zero coupon bonds and bears fixed interest rate to maturity of 2%. The bonds will mature on October 20, 2023. The bonds are 100% convertible into 2,287,432 shares, representing 7.29%, at a fixed conversion price of KRW 15,301 per share. The conversion period starts from October 20, 2021 and ends on September 20, 2023. The subscription date is September 28, 2020 and the transaction is expected to close on October 20, 2020. The transaction has been approved by the company's board of directors.